Surgery
Solos Endoscopy, Inc. Reports $90,005 in Sales Revenue for Fourth Quarter 2010
January 27, 2011 4:31 am | by Bio-Medicine.Org | News | CommentsBOSTON, Jan. 27, 2011 /- Solos Endoscopy, Inc. (OTCPK: SNDY) is pleased to announce that the Company generated revenues during the three months ended December 31, 2010 in the amount of $90,005. The revenue for the three month period is a result of instrument sales to over fifty Hospitals,...
Newly Published Data Demonstrates Caldolor® Significantly Reduces Pain and Morphine Use in Post-Operative Patients
January 27, 2011 3:35 am | by Bio-Medicine.Org | News | CommentsNASHVILLE, Tenn., Jan. 27, 2011 /- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) today announced the publication of data affirming the safety and efficacy of Caldolor® ( ibuprofen ) Injection in treating post-operative pain in hospitalized patients. A Phase III study published in...
Frost & Sullivan Recognizes Cohera Medical, Inc.® for Developing TissuGlu®, Its Pioneering Surgical Adhesive That Is Strong, Easy-To-Use, Biocompatible and Resorbable
January 25, 2011 4:31 am | by Bio-Medicine.Org | News | CommentsMOUNTAIN VIEW, Calif., Jan. 25, 2011 /- Based on its recent analysis of the surgical adhesives market, Frost & Sullivan recognizes Cohera Medical, Inc. with the 2010 Frost & Sullivan Award for New Product Innovation of the Year Award for TissuGlu. With surgeons looking for better...
More and More Celebrities Are Embracing Hair Restoration
January 24, 2011 10:32 pm | by Bio-Medicine.Org | News | CommentsLONDON, Jan. 25, 2011 /- An interesting statistic: more than half (55%) of hair loss sufferers would be more inclined to consider having a hair transplant if celebrities or public figures were more open about hair restoration surgery, and men are more likely to be influenced than women...
Independent Clinical Research Confirms Clinical Efficacy and Cost-Effectiveness of the SurgiCount Safety-Sponge® System
January 18, 2011 5:42 am | by Bio-Medicine.Org | News | CommentsIRVINE, Calif. and DUBLIN, Ohio, Jan. 18, 2011 /- Results of a multi-year, independent clinical research study on retained surgical sponges published in the February edition of The Joint Commission Journal on Quality and Patient Safety show that the institution implementing the SurgiCount...
New Online Resource Available Specifically for Patients and Their Caregivers Following a Heart Stent Procedure
January 18, 2011 5:42 am | by Bio-Medicine.Org | News | CommentsPARSIPPANY, N.J. and INDIANAPOLIS, Jan. 18, 2011 /- Today, patient support group Mended Hearts, in partnership with Daiichi Sankyo, Inc. and Eli Lilly and Company, launched the Stent Hub – an online resource for acute coronary syndrome (ACS) patients who were treated with...
Carbylan BioSurgery Completes Enrollment in Key Clinical Feasibility Study of Hydros and Hydros TA in Patients With Pain From Knee Osteoarthritis; Core Patent Issued
January 5, 2011 2:35 am | by Bio-Medicine.Org | News | CommentsPALO ALTO, Calif., Jan. 5, 2011 /- Carbylan BioSurgery, Inc. announced today the completion of patient enrollment in their double-blinded, multi-center COR1.0 feasibility trial to evaluate the safety and effectiveness of two products - Hydros and Hydros TA Joint Therapies - in patients...
<i>How I See It: </i>Uncertainty in medical device industry
January 4, 2011 7:38 pm | by Mass High Tech: The Journal of New England Technology | News | CommentsA recent development – the FDA's intention to rescind a 510(k) medical device registration held by ReGen Biologics Inc. – signals the FDA intends to broaden its regulatory powers, leaving companies in the medical device industry and those that invest in development of medical technologies...
Stryker Completes Acquisition of the Neurovascular Division of Boston Scientific
January 3, 2011 7:36 am | by Bio-Medicine.Org | News | CommentsKALAMAZOO, Mich., Jan. 3, 2011 /- Stryker Corporation (NYSE: SYK ) announced today the closing of its previously announced acquisition of the assets of the Neurovascular division of Boston Scientific, the global leader in the approximately $900 million worldwide neurovascular market,...
New Hope for Saving Diabetic Foot from Amputation
December 24, 2010 1:31 pm | by Bio-Medicine.Org | News | CommentsLOS ANGELES, Dec. 24, 2010 /- During ICMS (International Cellular Medicine Society www.cellmedicinesociety.org ) Annual International Congress on Regenerative and Cell Based Medicine Conference held on November 12, 2010 in Las Vegas, Nevada, it was announced that a patient with...
Zimmer Finalizes Acquisition of Chinese Orthopaedic Implant Leader Beijing Montagne Medical Device Co., Ltd.
December 21, 2010 4:33 am | by Bio-Medicine.Org | News | CommentsBEIJING, Dec. 21, 2010 /- Zimmer Holdings, Inc. (NYSE and SIX: ZMH), a global leader in musculoskeletal care, today announced that it has completed the acquisition of Beijing Montagne Medical Device Co., Ltd. The acquisition further enhances Zimmer's presence in the emerging Chinese...
PharMEDium Announces Propofol, Ready-to-Use, Single Patient, Syringe Service for Operating Room Anesthesia
December 20, 2010 8:34 am | by Bio-Medicine.Org | News | CommentsLAKE FOREST, Ill., Dec. 20, 2010 /- PharMEDium Services LLC, announced the addition of Propofol to its custom operating room anesthesia syringe preparation services. PharMEDium is the first compounder to offer Propofol in a pre-labeled, single patient, ready-to-use, tamper evident...
Accuray Establishes Medical Affairs Function
December 17, 2010 9:33 am | by Bio-Medicine.Org | News | CommentsSUNNYVALE, Calif., Dec. 17, 2010 /- Accuray Incorporated (Nasdaq: ARAY ), a global leader in the field of radiosurgery, announced today that the company has established a Medical Affairs function to accelerate CyberKnife data collection, utilization and referral patterns and to provide...
Microban International Announces Breakthrough in Antimicrobial Technologies for Medical Devices
December 16, 2010 9:36 am | by Bio-Medicine.Org | News | CommentsHUNTERSVILLE, N.C., Dec. 16, 2010 /- Hospital Acquired Infections (HAI's) are a serious health threat associated with over 100,000 deaths each year. These secondary infections following surgery are a major contributor to increased healthcare costs; experts estimate they add in...
Solta Medical Ships One Millionth Tip for Thermage and Fraxel Devices
December 16, 2010 6:32 am | by Bio-Medicine.Org | News | CommentsHAYWARD, Calif., Dec. 16, 2010 /- Solta Medical, Inc. (Nasdaq: SLTM ), the pioneer in fractional resurfacing and non-invasive skin tightening and a market leader in aesthetic skin treatments, today announced it has shipped its one millionth tip for the revolutionary Thermage and Fraxel...
Reportlinker Adds European Markets for Video, High-Tech and Integrated OT Equipment 2011
December 14, 2010 9:35 am | by Bio-Medicine.Org | News | CommentsNEW YORK, Dec. 14, 2010 /- Reportlinker.com announces that a new market research report is available in its catalogue: European Markets for Video, High-Tech and Integrated OT Equipment 2011...
Robotic Prostatectomy Expert Dr. David Samadi, MD Discusses Prostate Cancer Staging and Prostate Cancer Recurrence Study
December 14, 2010 9:35 am | by Bio-Medicine.Org | News | CommentsNEW YORK, Dec. 14, 2010 /- A new study in the journal Cancer shows that staging prostate cancer that has not metastasized beyond the prostate gland does predict the outcome, prognosis or risk of cancer recurrence after a radical prostatectomy. "This study confirms what many prostate...
MedShape Solutions, Inc. Secures Investment From IQT to Support U.S. Intelligence Community
December 13, 2010 4:37 am | by Bio-Medicine.Org | News | CommentsATLANTA, Dec. 13, 2010 /- MedShape Solutions, Inc., the world's leading developer of innovative orthopedic medical devices from shape memory materials, today announced a strategic investment and development agreement from In-Q-Tel (IQT), the strategic investment firm that identifies...
Ascension Orthopedics Implants PyroTITANâ„¢ in France
December 13, 2010 4:37 am | by Bio-Medicine.Org | News | CommentsAUSTIN, Texas, Dec. 13, 2010 /- Ascension Orthopedics, Inc., a market leader in PyroCarbon orthopedic implants, announces the first implantation of the PyroTITAN™ Humeral Resurfacing Implant in France. The PyroTITAN was implanted in a 68-year-old patient suffering from painful...
Injecting New Bone
December 12, 2010 7:34 pm | by Massachusetts Institute of Technology | News | CommentsAn artificial bone-like material could speed up recovery from injury.
Phase III Efficacy Data on Bevacizumab Plus Chemotherapy in Early Breast Cancer to be Presented
December 10, 2010 12:34 pm | by AACR | News | CommentsSAN ANTONIO - Results of the GeparQuinto study, randomized Phase III efficacy data on the use of bevacizumab plus chemotherapy to treat women with early breast cancer will be presented at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium.
Circulating Tumor Cells Predicted Recurrence, Death in Patients with Early-stage Breast Cancer
December 10, 2010 9:32 am | by AACR | News | CommentsSAN ANTONIO - The presence of one to four circulating tumor cells (CTCs) in the blood of early-stage breast cancer patients almost doubled patient's risk of cancer relapse and death, and five or more CTCs increased recurrence by 400 percent and death by 300 percent, according to Phase III...
Combination Therapy Reduced HER2-positive Breast Cancers
December 10, 2010 4:35 am | by AACR | News | CommentsSAN ANTONIO - A combination of lapatinib, trastuzumab and paclitaxel significantly improved tumor response rates than either agent alone among patients with HER2-positive breast cancers, according to data presented at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium, held...
Pertuzumab and Trastuzumab Combination Improved Efficacy for Women With HER2-positive Breast Cancer
December 10, 2010 4:34 am | by AACR | News | CommentsSAN ANTONIO - The combination of pertuzumab and trastuzumab had superior antitumor activity in women with early HER2-positive breast cancer, according to Phase II study results of the NeoSphere neoadjuvant trial.
Phase III Study Compared Neoadjuvant Therapy with Lapatinib or Trastuzumab for Early Breast Cancer
December 10, 2010 4:34 am | by AACR | News | CommentsSAN ANTONIO - Researchers presented Phase III efficacy data from the GeparQuinto study, a head-to-head comparison of neoadjuvant lapatinib and trastuzumab in combination with chemotherapy for patients with early breast cancer, at the 33rd Annual CTRC-AACR San Antonio Breast Cancer...
